Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

N43: the "help-line telephone" form: a new telemedical support for managing patients with ibdECCO'25
Year: 2025
Authors: Povoli, A.(1)*;Grubissa, S.(1);Molino, L.(2);Marino, M.(1);Berretti, D.(1);
(1)Azienda Sanitaria Universitaria Friuli Centrale, Gastroenterology, Udine, Italy;(2)Cattolica university- gemelli hostipal- Roma- Italy, Gastroenterology, Rome, Italy;

DeBlois, D., Millefoglie, M. (2015). Telehealth: enhancing collaboration, improving care coordination. Nursing Management; 46:10–12. 
Huang, V., Reich, K., Fedorak, R. (2014). Distance management of inflammatory bowel disease: systematic review and meta-analysis. World Journal of Gastroenterology; 20:829–42.Win, A. (2015) Telehealth can bridge the gap for rural, disabled, and elderly patients. J Am Med Dir Assoc; 16:268–9.
Turner, D., Ricciuto, A., Lewis, A., D'Amico, F., Dhaliwal, J., Griffiths, A.M., Bettenworth, D., Sandborn, W.J., Sands, B.E., Reinisch, W., Schölmerich, J., Bemelman, W., Danese, S., Mary, J.Y., Rubin, D.,
Colombel, J.F., Peyrin-Biroulet, L., Dotan, I., Abreu, M.T., Dignass, A. (2021). STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology; 160: 1570-1583.
Jackson, C.A., Clatworthy, J., Robinson, A., Horne, R. (2010). Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol; 105: 525-539.
Del Hoyo, J., Millán, M., Garrido-Marín, A., Aguas, M. (2010). Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers. World journal of gastroenetology; 29(7):1139-1156.

N44: Telenursing for patients with inflammatory bowel disease: an interview study of nursesECCO'25
Year: 2025
Authors: Kawakami, A.(1)*;Tanaka, M.(1);Sakagami, K.(2);Moribe, Y.(3);Kunisaki, R.(4);
(1)Institute of Science Tokyo, Adult Health Nursing, Tokyo, Japan;(2)Kinshukai Infusion Clinic, Gastroenterology, Osaka, Japan;(3)Institute of Science Tokyo Hospital, Nursing department, Tokyo, Japan;(4)Yokohama City University Medical Center, Inflammatory Bowel Disease Center, Yokohama, Japan;
N45: The Words of Bowels: Exploring Crohn's Disease through MetaphorsECCO'25
Year: 2025
Authors: Sözeri Öztürk, E.(1);Kırca, K.(2);Uçan, Ş.(3)*;
(1)Gazi University, Faculty of Nursing, Ankara, Turkey;(2)Kırıkkale University, Faculty of Health Sciences- Nursing Department, Kırıkkale, Turkey;(3)Gazi Hospital, İnflammatory Bowel Diseases Outpatient Clinic, Ankara, Turkey;
N46: Exploring the impact of initiating a Patient Reported Outcome Measure (PROM) by utilising an Inflammatory Bowel Disease (IBD) pre clinic questionnaire prior to patients attending an IBD outpatients clinicECCO'25
Year: 2025
Authors: Scott, G.(1)*;
(1)East Kent Hospitals University Foundation Trust, Gastroenterology, Ramsgate, United Kingdom;
N47: Implementation of a Nurse Led Vaccination clinic for Inflammatory Bowel Disease patientsECCO'25
Year: 2025
Authors: Gleeson , S.(1)*;Keogh, A.(2);O Sullivan , C.(1);Sugrue , K.(1);McCarthy , J.(1);Buckley , M.(1);Moran , C.(1);Sheehan , D.(1);McDonald , C.(1);O Brien , L.(1);Twomey , R.(1);
(1)Mercy University Hospital, Inflammatory Bowel Disease, Cork, Ireland; (2)Galway University Hospital Ireland, IBD department, Galway, Ireland;

T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N Viget, Y Zabana, S Vavricka, on behalf of the European Crohn’s and Colitis Organisation [ECCO], ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease, Journal of Crohn's and Colitis, Volume 15, Issue 6, June 2021, Pages 879–913, https://doi.org/10.1093/ecco-jcc/jjab052

N48: Fatigue in Inflammatory Bowel Diseases: A Bibliometric and Content AnalysisECCO'25
Year: 2025
Authors: Terzi, A.(1);Artan, Y.(2)*;Yıldırım, Y.(3);Deveci Kocakoç, İ.(4);
(1)Artvin Coruh University, Faculty of Health Science- Department of Nursing, Artvin, Turkey;(2)Ardahan University, Faculty of Health Science- Department of Nursing, Ardahan, Turkey;(3)Ege University, Faculty of Nursing- Department of Internal Medicine Nursing, İzmir, Turkey;(4)Dokuz Eylul University, Faculty of Economics and Administrative Sciences- Department of Econometrics, İzmir, Turkey;

Nocerino, A., Nguyen, A., Agrawal, M., Mone, A., Lakhani, K., & Swaminath, A. (2020). Fatigue in inflammatory bowel diseases: etiologies and management. Advances in therapy, 37, 97-112. Van Langenberg, D. R., & Gibson, P. R. (2010). Systematic review: fatigue in inflammatory bowel disease. Alimentary pharmacology & therapeutics, 32(2), 131-143.  
Van Langenberg, D. R., & Gibson, P. R. (2010). Systematic review: fatigue in inflammatory bowel disease. Alimentary pharmacology & therapeutics, 32(2), 131-143.

N49: Sexual and reproductive health of Australian women who live with Inflammatory Bowel Disease.ECCO'25
Year: 2025
Authors: O'reilly, K.(1)*;Peters, K.(1);Holroyd, E.(2);
(1)Western Sydney University, Nursing and Midwifery, Penrith, Australia;(2)Auckland University of Technology, Nursing and Midwifery, Auckland, New Zealand;

Anderson, K., & Jack, D. (1991). Learning to listen: Interview techniques and analyses. In S. Berger-Gluck, & D. Patai (Eds.), Women’s words: The feminist practice of oral history (pp.11 – 26). Routledge Publications.
Braun, V., & Clarke, V. (2016). Thematic Analysis. In E. Lyons & A. Coyle (Eds.), Analysing qualitative data in Psychology (2nd ed., pp.84 – 103). SAGE publications.
Hesse- Biber, S. (2014). Feminist approaches to in-depth interviewing. In S. Hesse- Biber (Ed.), Feminist Research Practice (pp. 182 – 232). SAGE publications.

N51: How to guide, for selecting and managing High Cost Drugs in Inflammatory Bowel Disease (IBD)ECCO'25
Year: 2025
Authors: Scott , G.(1)*;Abreu , B.(2)*;
(1)East Kent Hospitals University Foundation Trust, Gastroenterology, Ramsgate, United Kingdom;(2)East Kent Hospitals University Foundation Trust, Gastroenterology, Margate, United Kingdom;
N52: Transition care does not end at transfer of treatmentECCO'25
Year: 2025
Authors: Crook, K.P.(1)*;Arebi, N.(2);Hart, A.(2);Hyer, W.(3);Adio, J.(4);
(1)London Northwest University Healthcare NHS Trust / St Mark's Hospital, Department of Paediatric Gastroenterology, London, United Kingdom;(2)St Mark's Hospital, Inflammatory Bowel Disease, London, United Kingdom;(3)London Northwest University Healthcare NHS Trust / St Mark's Hospital, Department of Paediatric Gastroenterology, London, United Kingdom;(4)St Mark's Hospital, Inflammatory Bowel Disease Nursing, London, United Kingdom;
N53: Managing an ever-increasing inflammatory bowel disease helpline serviceECCO'25
Year: 2025
Authors: Scott, G.(1)*;Brown, A.(2);Roads, N.(3);Abreu, B.(2);Rai, K.(4);Naeck-Boolauky, P.(4);Loxley, J.(2);
(1)East Kent Hospitals University Foundation Trust, Gastroenterology, Ramsgate, United Kingdom;(2)East Kent Hospitals University Foundation Trust, Gastroenterology, Margate, United Kingdom;(3)East Kent Hospitals University Foundation Trust, Gastroenterology, Canterbury, United Kingdom;(4)East Kent Hospitals University Foundation Trust, Gastroenterology, Ashford, United Kingdom;
P0001: Single-cell profiling reveals distinct γδ T cell subsets with protective and pathogenic roles in Ulcerative ColitisECCO'25
Year: 2025
Authors: Mayer, L.(1,2)*;Arnold, J.(1,3);Reuter, N.(1);Pattekar, A.(2,4);Ohtani, T.(4);Bruder, K.(1);Ribeiro, M.(5);Siwicki, R.(5);Obwegs, D.(1,3);Stahl, E.(1);Kolter, J.(6,7);Mansoori Moghadam, Z.(6,7);Alaswad, A.(8);Li, Y.(8);Lewis, J.D.(2);Wu, G.D.(2);Bewtra, M.(2);Tomov, V.T.(2);Bengsch, B.(1,9);Thimme, R.(1);Hasselblatt, P.(1);Picelli, S.(5);Hofmann, M.(1);Sagar, S.(1);
(1)University Medical Center Freiburg, Clinic for Internal Medicine II- Gastroenterology- Hepatology- Endocrinology- and Infectious Diseases, Freiburg, Germany;(2)Department of Medicine, Division of Gastroenterology and Hepatology- Perelman School of Medicine- University of Pennsylvania, Philadelphia, United States;(3)Faculty of Biology, University of Freiburg, Freiburg, Germany;(4)Institute for Immunology, Perelman School of Medicine- University of Pennsylvania, Philadelphia, United States;(5)Single cell genomics platform, Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland;(6)Institute for Immunodeficiency, Center for Chronic Immunodeficiency- Medical Center and Faculty of Medicine- University of Freiburg, Freiburg, Germany;(7)Institute for Infection Control and Prevention, Medical Center and Faculty of Medicine- University of Freiburg, Freiburg, Germany;(8)Centre for Individualised Infection Medicine and TWINCORE, joint ventures between the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany;(9)Signalling Research Centres BIOSS and Centre for Integrative Biological Signalling Studies CIBSS, University of Freiburg, Freiburg, Germany;
P0002: Identification of Infliximab and Adalimumab -derived peptides using MHC class II antibody mediated immunopeptidomics and mass spectrometry: implications for drug re-design.ECCO'25
Year: 2025
Authors: Bedke, N.(1)*;Liao, H.(2);Nicastri, A.(3);Parker, R.(3);Dzhoneva, A.(3);Noble, A.(1);Al-Hillawi, L.(1);Brain, O.(1);Satsangi, J.(1);Ternette, N.(2);
(1)University of Oxford, Translational Gastroenterology and Liver Unit, Oxford, United Kingdom;(2)University of Dundee, School of Life Sciences, Dundee, United Kingdom;(3)University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom;

References

1) Doherty R, Liao H, Satsangi J, Ternette N. Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab. Gastroenterology. 2020, 159: 784-787.

2) Sazonovs A, Kennedy N, Moutsianas L, et al. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease Gastroenterology. 2020, 158:189-199

3) Ternette N, Liao H., Satsangi J. Association of the HLA DQA1*05 allelic gene variants with immunogenicity to anti-TNF therapeutics - important differences between infliximab and adalimumab. Journal of Crohn's and Colitis. 2024

P0003: Differential Effects of JAK Inhibitors on Epithelial-Immune Interaction in Inflammatory Bowel DiseaseECCO'25
Year: 2025
Authors: Floor, E.(1,2)*;van der Kooij, R.(2);van Wijk, F.(3);Oldenburg, B.(1);Vercoulen, Y.(2);
(1)UMC Utrecht, Gastroenterology, Utrecht, The Netherlands;(2)UMC Utrecht, Center for Molecular Medicine, Utrecht, The Netherlands;(3)UMC Utrecht, Center for Translational Immunology, Utrecht, The Netherlands;

1. Zaderer, V., Hermann, M., Lass-Flörl, C., Posch, W., and Wilflingseder, D. (2019). Turning the World Upside-Down in Cellulose for Improved Culturing and Imaging of Respiratory Challenges within a Human 3D Model. Cells 8. https://doi.org/10.3390/cells8101292.

2. Jelinsky, S.A., Derksen, M., Bauman, E., Verissimo, C.S., van Dooremalen, W.T.M., Roos, J.L., Higuera Barón, C., Caballero-Franco, C., Johnson, B.G., Rooks, M.G., et al. (2023). Molecular and Functional Characterization of Human Intestinal Organoids and Monolayers for Modeling Epithelial Barrier. Inflamm Bowel Dis 29, 195–206. https://doi.org/10.1093/ibd/izac212.

3. Fujii, M., Matano, M., Toshimitsu, K., Takano, A., Mikami, Y., Nishikori, S., Sugimoto, S., and Sato, T. (2018). Human Intestinal Organoids Maintain Self-Renewal Capacity and Cellular Diversity in Niche-Inspired Culture Condition. Cell Stem Cell 23, 787-793.e6. https://doi.org/10.1016/j.stem.2018.11.016.

P0004: Transcriptomic profiling as a tool for prediction of endoscopic inflammation in quiescent Crohn's Disease patientsECCO'25
Year: 2025
Authors: Meningher, T.(1)*;Finkel, O.(1);Nayshool, O.(1);Fudim, E.(1);.Yavzori, M.(1);Picard, O.(1);Talan-Asher, A.(1);Yablekovitch, D.(1);kopylov, U.(1);Ben-Horin, S.(1);Ungar, B.(1);
(1)Sheba Medical Center, Gastroenterology Institute, Ramat Gan, Israel;

1. Friedrich, M., Pohin, M., Jackson, M. A., Korsunsky, I., Bullers, S. J., Rue-Albrecht, K., Christoforidou, Z., Sathananthan, D., Thomas, T., Ravindran, R., Tandon, R., Peres, R. S., Sharpe, H., Wei, K., Watts, G. F. M., Mann, E. H., Geremia, A., Attar, M., Barone, F., … Powrie, F. M. (2021). IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nature Medicine, 27(11), 1970–1981. https://doi.org/10.1038/s41591-021-01520-5 2. Dan, S., Ungar, B., Ben-Moshe, S., Bahar Halpern, K., Yavzori, M., Fudim, E., Picard, O., Abitbol, C. M., Harnik, S., Barshack, I., Kopylov, U., Ben-Horin, S., & Itzkovitz, S. (2023). Distal Fecal Wash Host Transcriptomics Identifies Inflammation Throughout the Colon and Terminal Ileum. Cmgh, 16(1), 1–15. https://doi.org/10.1016/j.jcmgh.2023.02.002
2. Dan, S., Ungar, B., Ben-Moshe, S., Bahar Halpern, K., Yavzori, M., Fudim, E., Picard, O., Abitbol, C. M., Harnik, S., Barshack, I., Kopylov, U., Ben-Horin, S., & Itzkovitz, S. (2023). Distal Fecal Wash Host Transcriptomics Identifies Inflammation Throughout the Colon and Terminal Ileum. Cmgh, 16(1), 1–15. https://doi.org/10.1016/j.jcmgh.2023.02.002

P0005: Transcriptomic analysis reveals molecular differences between intestinal tuberculosis and ileal Crohn's DiseaseECCO'25
Year: 2025
Authors: Tang, Q.(1);Tian, C.(1);Ye, L.(1);Huang, L.(1)*;Cao, Q.(1);
(1)Sir Run Run Shaw Hospital- Zhejiang University School of Medicine, Inflammatory Bowel Disease Center, Hangzhou, China;
P0006: Developmentally endothelial locus-1 promotes intestinal inflammation resolution through inhibition of the Cmpk2-cGAS-STING pathway and regulates reparatory macrophage transitionECCO'25
Year: 2025
Authors: Tao, M.(1)*;Chen, C.(2);Fu, Y.(1);
(1)Union Hospital- Tongji Medical College- Huazhong University of Science and Technology, Department of Gastroenterology, wuhan, China;(2)The First Affiliated Hospital of USTC- Division of Life Sciences and Medicine- University of Science and Technology of China, Department of Gastroenterology, hefei, China;
P0007: mAb-based targeting of the eAGR2-Fibrinogen interaction as a promising new therapy in Inflammatory Bowel DiseaseECCO'25
Year: 2025
Authors: Kantar, D.(1);Bachiri, K.(2);Villemin, C.(2);Collini, F.(2);Treton, X.(3);Beq, S.(2)*;Coyaud, E.(1);
(1)Prism laboratory- Inserm U1192- University of Lille, Department of Biology, Lille, France;(2)Thabor therapeutics, Research and Development, Paris, France;(3)Institut des MICI, Groupe hospitalier Ambroise Pare Hartmann, Neuilly, France;

1. Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties. Fessart D, Domblides C, Avril T, et al. Elife. 2016 May 30;5:e13887.
2. Control of anterior GRadient 2 (AGR2) dimerization links endoplasmic reticulum proteostasis to inflammation. Maurel M, Obacz J, Avril T, et al. EMBO Mol Med. 2019 Jun;11(6):e10120.
3. Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn's Disease Fibrosis. Vieujean S, Hu S, Bequet E, et al. J Crohns Colitis. 2021 Oct 7;15(10):1737-1750.
4. Fibrinogen as a key regulator of inflammation in disease. Davalos, D., Akassoglou, K. Semin Immunopathol  2012 Vol 34: 43–62. 

P0008: A multi-omics approach across multiple chronic inflammatory diseases identifies a distinct type-1-interferon endotype of Inflammatory Bowel DiseaseECCO'25
Year: 2025
Authors: Mishra, N.(1);Tran, F.(1,2)*;Kimmig, F.(1);Aden, K.(1,2);Credidio, G.(1);Wolff, C.(1);Ruge, T.(1);Blase, J.I.(1);Bernardes, J.P.(1);Ellinghaus, D.(1);Zeuner, R.(3);Frey, N.(4);Lieb, W.(5);Franke, A.(1);Schreiber, S.(2);Rosenstiel, P.(1);
(1)University Hospital Schleswig-Holstein- Campus Kiel, Insitute of Clinical Molecular Biology, Kiel, Germany;(2)University Hospital Schleswig-Holstein- Campus Kiel, Department of Internal Medicine I/Gastroenterology, Kiel, Germany;(3)University Hospital Schleswig-Holstein- Campus Kiel, Department of Internal Medicine I- Section of Rheumatology, Kiel, Germany;(4)Heidelberg University Hospital, Department of Cardiology- Angiology- and Pneumology, Heidelberg, Germany;(5)University Hospital Schleswig-Holstein- Campus Kiel, Institute of Epidemiology, Kiel, Germany;

This project has received funding from the DFG Cluster of Excellence 2167 "Precision medicine in chronic inflammation", the BMBF (e:Med Network iTREAT 01ZX2202A), the European Union/Horizon2020 (SYSCID, No 733100) and the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR) and No 853995 (ImmUniverse).The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. The content provided in this publication reflects the author's views only. Neither the Innovative Medicines Initiative (IMI JU) nor the European Commission are responsible for any use that may be made of the information it contains.

P0009: Comparative analysis of ileal mucus in healthy individuals and Crohn’s Disease patients using scanning electron microscopy suggests changes in network structureECCO'25
Year: 2025
Authors: Mönch, P.W.(1)*;Kramer, C.(1);Timm, S.(2);Kerkhoff, Y.(3);Ludwig, K.(3);Ochs, M.(2);Siegmund, B.(1);
(1)Charité Universitätsmedizin Berlin, Department of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(2)Charité Universitätsmedizin Berlin, Core Facility Electron Microscopy, Berlin, Germany;(3)Freie Universität Berlin, Institute of Chemistry and Biochemistry, Berlin, Germany;

1. Johansson, M. E. V., Sjövall, H., & Hansson, G. C. (2013). The gastrointestinal mucus system in health and disease. Nature Reviews Gastroenterology & Hepatology, 10(6), 352-361. https://doi.org/10.1038/nrgastro.2013.35
2. Bansil, R., & Turner, B. S. (2018). The biology of mucus: Composition, synthesis and organization. Advanced Drug Delivery Reviews, 124, 3-15. https://doi.org/10.1016/j.addr.2017.09.019
3. Kramer, C., RulD, H., Ziegler, J. F., et al. (2024). Ileal mucus viscoelastic properties diDer in Crohn’s disease. Mucosal Immunology, 17(4), 713-722. https://doi.org/10.1038/s41385-023-00567-9
4. Atreya, R., Siegmund, B. (2021). Location is important: differentiation between ileal and colonic Crohn’s disease. Nature Reviews Gastroenterology & Hepatology, 18(8), 544-558. https://doi.org/10.1038/s41575-021-00452-3

P0010: Characterization of proliferating memory CD4⁺ T cells reveals a distinct immune signature in anti-α4β7 integrin therapy non-responders Inflammatory Bowel Disease patientsECCO'25
Year: 2025
Authors: Cancino, C.(1,2)*;Horn, V.(1,2,3);Obermayer, B.(4,5);Fritz, K.(1,2);Nguyen, A.(1,6);Juhran, K.(1,2);Bösel, D.(1,2);Conrad, T.(7,8);Sonnenberg, E.(1);Weidinger, C.(1);Siegmund, B.(1);Thurley, K.(2,9);Hegazy, A.(1,2,5);
(1)Charité Universitätsmedizin Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(2)Deutsches Rheuma-Forschungszentrum, ein Institut der Leibniz-Gemeinschaft, Berlin, Germany;(3)Weill Cornell Medicine- Cornell University, Department of Medicine- Division of Gastroenterology and Hepatology, New York, United States;(4)Berlin Institute of Health at Charité Universitätsmedizin Berlin, Core Unit Bioinformatics, Berlin, Germany;(5)Berlin Institute of Health at Charité Universitätsmedizin Berlin, Berlin Institute of Health Academy- Clinician Scientist Program, Berlin, Germany;(6)Monash University and Alfred Health, Department of Gastroenterology- Central Clinical School, Melbourne, Australia;(7)Max Delbrück Center for Molecular Medicine in the Helmholtz Association MDC, Genomics Technology Platform, Berlin, Germany;(8)Berlin Institute of Health at Charité Universitätsmedizin Berlin, Core Unit Genomics, Berlin, Germany;(9)University Hospital Bonn, Institute for Experimental Oncology- Biomathematics Division, Bonn, Germany;